ATP6V1A and developmental and epileptic encephalopathy: More recently, several de novo missense mutations in ATP6V1A have been described in patients with DEE of variable severity, with symptoms ranging from moderate intellectual disability (ID) and seizures to early-onset DEE with premature lethality [19,20].